Results 111 to 120 of about 31,772 (155)
Some of the next articles are maybe not open access.
Diagnosis and Treatment of Malignant Carcinoid Syndrome
JAMA - Journal of the American Medical Association, 1974THE malignant carcinoid syndrome has challenged the skills of the clinician, biochemist, and pharmacologist since its original description by Biorck et al 1 22 years ago. Although attention originally centered on a symptom complex and a serotonin-producing midintestinal neoplasm that had metastasized to the liver, the carcinoid syndrome has now been ...
exaly +3 more sources
The malignant carcinoid syndrome
The American Journal of Digestive Diseases, 1966exaly +3 more sources
Treatment of the Malignant Carcinoid Syndrome
New England Journal of Medicine, 1986Joseph Rubin +2 more
exaly +2 more sources
Archives of Surgery, 1959
The malignant carcinoid syndrome is manifested by (1) paroxysmal flushing, (2) chronic diarrhea, (3) respiratory distress, and (4) valvular heart disease. These abnormalities result from a marked increase in the amount of circulating serotonin. The abnormal clinical findings in this syndrome result principally from the action of serotonin on the ...
Wilson, Harwell, Storer, Edward H.
openaire +3 more sources
The malignant carcinoid syndrome is manifested by (1) paroxysmal flushing, (2) chronic diarrhea, (3) respiratory distress, and (4) valvular heart disease. These abnormalities result from a marked increase in the amount of circulating serotonin. The abnormal clinical findings in this syndrome result principally from the action of serotonin on the ...
Wilson, Harwell, Storer, Edward H.
openaire +3 more sources
Therapy of the Malignant Carcinoid Syndrome
Annals of Internal Medicine, 1965Excerpt The therapy of the malignant carcinoid syndrome presents a unique challenge to physicians caring for patients with this unusual disease.
openaire +2 more sources
Metastatic Carcinoid Tumors and the Malignant Carcinoid Syndrome
Annals of the New York Academy of Sciences, 1994Patients with metastatic carcinoid tumors and the malignant carcinoid syndrome have benefited immensely from diagnostic and therapeutic advances during the past decade. Magnetic resonance imaging and whole body scintigraphy with radiolabelled analogues of somatostatin have improved our ability to diagnose, detect, stage and follow response to therapy ...
openaire +2 more sources
Archives of Internal Medicine, 1966
SINCE the early descriptions of the carcinoid syndrome, 1-4 it has been assumed that the associated hyperserotonemia is responsible for the symptoms and development of the cardiac lesions. These lesions, which appear mainly on the right side of the heart, are characterized by subendocardial proliferation of fibrous tissue resulting in thickening of the
openaire +1 more source
SINCE the early descriptions of the carcinoid syndrome, 1-4 it has been assumed that the associated hyperserotonemia is responsible for the symptoms and development of the cardiac lesions. These lesions, which appear mainly on the right side of the heart, are characterized by subendocardial proliferation of fibrous tissue resulting in thickening of the
openaire +1 more source
Gastrointestinal carcinoids and the malignant carcinoid syndrome.
Surgery, gynecology & obstetrics, 1981The records of 59 patients with gastrointestinal carcinoid tumors at The New York Hospital from 1948 to 1978 were reviewed. Forty-seven instances were diagnosed surgically; 12 were identified on autopsy specimens. The average age at diagnosis was 55.8 years. No association with duodenal ulcer or carcinoma could be made. The appendix was the mose common
H, Beaton, W, Homan, P, Dineen
openaire +1 more source
Abdominal Crisis in the Malignant Carcinoid Syndrome
Archives of Internal Medicine, 1966EPISODES of acute abdominal pain during the course of the malignant carcinoid syndrome often present a major challenge to physicians caring for patients with this unique disease. The primary tumor (usually in the small intestine) rarely causes symptoms until widespread metastases occur.
openaire +2 more sources
Cancer, 1991
Sixteen patients with metastatic neuroendocrine tumors and the malignant carcinoid syndrome were treated with cyproheptadine (Periactin, Merck, Sharp & Dohme, West Point, PA) at maximum tolerable doses that ranged from 12 to 48 mg daily. Usual side effects were mild sedation and dry mouth, but three patients found it impossible to sustain treatment due
C G, Moertel, L K, Kvols, J, Rubin
openaire +2 more sources
Sixteen patients with metastatic neuroendocrine tumors and the malignant carcinoid syndrome were treated with cyproheptadine (Periactin, Merck, Sharp & Dohme, West Point, PA) at maximum tolerable doses that ranged from 12 to 48 mg daily. Usual side effects were mild sedation and dry mouth, but three patients found it impossible to sustain treatment due
C G, Moertel, L K, Kvols, J, Rubin
openaire +2 more sources